Related references
Note: Only part of the references are listed.Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Sven Francque et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Role of liver sinusoidal endothelial cells in liver diseases
Jordi Gracia-Sancho et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Animal models for liver disease - A practical approach for translational research
Yulia A. Nevzorova et al.
JOURNAL OF HEPATOLOGY (2020)
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Sander Lefere et al.
JOURNAL OF HEPATOLOGY (2020)
Novel therapeutics for portal hypertension and fibrosis in chronic liver disease
Sergi Guixe-Muntet et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue
Samuel J. Daniels et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial
Candid Villanueva et al.
LANCET (2019)
A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease
Zoe Boyer-Diaz et al.
NUTRIENTS (2019)
Hepatic microcirculation and mechanisms of portal hypertension
Jordi Gracia-Sancho et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Dual PPAR/agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
Mukul R. Jain et al.
LIVER INTERNATIONAL (2018)
Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension
Hung-Cheng Tsai et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications
Marti Ortega-Ribera et al.
BIOTECHNOLOGY AND BIOENGINEERING (2018)
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
Benaissa Boubia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension
Dinesh Mani Tripathi et al.
GASTROENTEROLOGY (2018)
The Selective Peroxisome Proliferator-Activated Receptor-Delta Agonist Seladelpar Reverses Nonalcoholic Steatohepatitis Pathology by Abrogating Lipotoxicity in Diabetic Obese Mice
Fahrettin Haczeyni et al.
HEPATOLOGY COMMUNICATIONS (2017)
The New-Generation Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis
Guillaume Wettstein et al.
HEPATOLOGY COMMUNICATIONS (2017)
PPARs and nonalcoholic fatty liver disease
Kim H. H. Liss et al.
BIOCHIMIE (2017)
The role and regulation of the peroxisome proliferator activated receptor alpha in human liver
Sander Kersten et al.
BIOCHIMIE (2017)
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments
Jaume Bosch et al.
JOURNAL OF HEPATOLOGY (2015)
Liver fibrosis and repair: immune regulation of wound healing in a solid organ
Antonella Pellicoro et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
E. M. Zardi et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Bart Staels et al.
HEPATOLOGY (2013)
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins
Giusi Marrone et al.
JOURNAL OF HEPATOLOGY (2013)
Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis
Feng Zhang et al.
CELLULAR SIGNALLING (2012)
PPAR alpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats
Aina Rodriguez-Vilarrupla et al.
JOURNAL OF HEPATOLOGY (2012)
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Keiko Iwaisako et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs
Marion Peyrou et al.
PPAR RESEARCH (2012)
Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma
Andrzej Zieleniak et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2008)
The management of portal hypertension: Rational basis, available treatments and future options
Jaime Bosch et al.
JOURNAL OF HEPATOLOGY (2008)
Vascular deterioration in cirrhosis - The big picture
Jaime Bosch
JOURNAL OF CLINICAL GASTROENTEROLOGY (2007)
From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
JN Feige et al.
PROGRESS IN LIPID RESEARCH (2006)
Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells
F Marra et al.
GASTROENTEROLOGY (2000)
Share Paper
